Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 10/20 | 0.44 |
| ▸ | AKR1A1 | P14550 | 9/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 4/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25063677 | 0.80 | AKR1A1 (0.43) | AKR1B1AKR1A1ITGA4TNFADAM17 | |
| SCHEMBL9671809 | 0.77 | ITGA4 (0.68) | AKR1B1AKR1A1ITGA4CRHBPCRHR2 | |
| SCHEMBL9671558 | 0.69 | AKR1B1 (0.59) | AKR1B1AKR1A1ITGA4CRHBPCRHR2 | |
| SCHEMBL9672105 | 0.69 | AKR1A1 (0.68) | AKR1B1AKR1A1ITGA4 | |
| SCHEMBL10907091 | 0.69 | AKR1B1 (0.68) | AKR1B1AKR1A1ITGA4CRHBPCRHR2 | |
| SCHEMBL21095592 | 0.69 | ITGA4 (0.61) | AKR1B1AKR1A1ITGA4ADAM17CRHBP | |
| SCHEMBL21095582 | 0.67 | ITGA4 (0.58) | AKR1B1AKR1A1ITGA4CRHBPCRHR2 | |
| SCHEMBL25063575 | 0.67 | ITGA4 (0.58) | AKR1B1AKR1A1ITGA4CRHBPCRHR2 | |
| SCHEMBL20845782 | 0.67 | AKR1B1 (0.69) | AKR1B1AKR1A1ITGA4 | |
| SCHEMBL22380690 | 0.67 | AKR1B1 (0.73) | AKR1B1AKR1A1ITGA4ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11576900-B2 | Compositions and methods of reducing serum cholesterol and PCSK9 | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-02-14 | — | — | US | disclosed |
| US-20200268717-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | CASE WESTERN RESERVE UNIVERSITY | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11576900-B2 | Compositions and methods of reducing serum cholesterol and PCSK9 | PCSK9, HMGCR, PCSK7 | AKR1B1 9/4885AKR1A1 8/4885ITGA4 4832/4885 |
| US-20200268717-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | PCSK9, HMGCR, PCSK7 | AKR1B1 9/4885AKR1A1 8/4885ITGA4 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.